Skip to main content
. Author manuscript; available in PMC: 2016 Dec 16.
Published in final edited form as: Vaccine. 2015 Nov 10;33(51):7168–7175. doi: 10.1016/j.vaccine.2015.10.135

Figure 3. Deposition of human C4b on live meningococci by vaccine-induced macaque anti-FHbp antibodies.

Figure 3

The macaque sera were heat-inactivated and tested at a 1:40 dilution in the presence of 5% human serum that had been depleted of IgG as a source of complement. The test strain was the H44/76 mutant with FHbp ID 15. A. C4b deposition elicited by representative post-immunization sera after dose 2 of vaccine (solid line) or dose 3 (dashed line). The gray region denotes bacteria with 5% human complement but no macaque serum. B. Median fluorescence intensities (MFIs) for C4b deposition elicited by macaque sera (N=6 per group). The horizontal error bars represent geometric means. The difference between the vaccinated post-dose 2 and post-dose 3 in the FHlow baselin group was statistically significant. **p=0.0065.